159 related articles for article (PubMed ID: 23848362)
1. Off-target effects of MEK inhibitors.
Wauson EM; Guerra ML; Barylko B; Albanesi JP; Cobb MH
Biochemistry; 2013 Aug; 52(31):5164-6. PubMed ID: 23848362
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
3. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.
Lee HR; Lee J; Kim HJ
Pharmacol Res; 2019 Nov; 149():104466. PubMed ID: 31562895
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitors induce interleukin-5 expression in mouse macrophages and lymphocytes.
Li X; Cao X; Zhang X; Kang Y; Zhang W; Yu M; Ma C; Han J; Duan Y; Chen Y
Biochem Biophys Res Commun; 2016 May; 473(4):939-946. PubMed ID: 27045084
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia enhances FGF2- and VEGF-stimulated human placental artery endothelial cell proliferation: roles of MEK1/2/ERK1/2 and PI3K/AKT1 pathways.
Wang K; Jiang YZ; Chen DB; Zheng J
Placenta; 2009 Dec; 30(12):1045-51. PubMed ID: 19892399
[TBL] [Abstract][Full Text] [Related]
8. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.
Shibazaki S; Yu Z; Nishio S; Tian X; Thomson RB; Mitobe M; Louvi A; Velazquez H; Ishibe S; Cantley LG; Igarashi P; Somlo S
Hum Mol Genet; 2008 Jun; 17(11):1505-16. PubMed ID: 18263604
[TBL] [Abstract][Full Text] [Related]
9. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
10. Effect of inhibitors of mitogen-activated protein kinase kinase on alpha(1B)-adrenoceptor phosphorylation.
Alcántara-Hernández R; Adolfo García-Sáinz J
Auton Autacoid Pharmacol; 2009 Jan; 29(1-2):13-23. PubMed ID: 19302552
[TBL] [Abstract][Full Text] [Related]
11. Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm.
Osabe M; Negishi M
J Biol Chem; 2011 Oct; 286(41):35763-35769. PubMed ID: 21873423
[TBL] [Abstract][Full Text] [Related]
12. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly.
Tsai J; Qiu W; Kohen-Avramoglu R; Adeli K
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):211-8. PubMed ID: 17038630
[TBL] [Abstract][Full Text] [Related]
13. Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059.
Clemons AP; Holstein DM; Galli A; Saunders C
Pancreas; 2002 Oct; 25(3):251-9. PubMed ID: 12370536
[TBL] [Abstract][Full Text] [Related]
14. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.
Galuppo M; Esposito E; Mazzon E; Di Paola R; Paterniti I; Impellizzeri D; Cuzzocrea S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jul; 384(1):21-37. PubMed ID: 21533992
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
17. MEK/Erk-based negative feedback mechanism involved in control of Steel Factor-triggered production of Krüppel-like factor 2 in mast cells.
Marschall JS; Wilhelm T; Schuh W; Huber M
Cell Signal; 2012 Apr; 24(4):879-88. PubMed ID: 22182511
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.
Zennadi R
PLoS One; 2014; 9(10):e110306. PubMed ID: 25330306
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.
Alesiani D; Cicconi R; Mattei M; Bei R; Canini A
Int J Oncol; 2009 Jun; 34(6):1727-35. PubMed ID: 19424591
[TBL] [Abstract][Full Text] [Related]
20. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
